Literature DB >> 6823179

Survival rates in 548 patients with multiple neoplasms of the upper aerodigestive tract.

J L Gluckman, J D Crissman.   

Abstract

The high incidence of multiple primary carcinomas occurring in the upper aerodigestive tract is well documented, with the accepted incidence being as high as 20-30%. The full clinical significance of this phenomenon is, however, only now becoming apparent. Herein 548 cases of documented multiple primary neoplasms, presenting initially in the upper aerodigestive tract, are evaluated retrospectively to establish the survival in these patients. The overall 5 years survival rate after diagnosis of the second neoplasm was found to be 22.3% which was significantly lower than a control group. The reasons for this poor survival are considered. These include: 1. the high incidence of second cancers developing in the lung and esophagus which have an extremely poor survival rate; 2. the frequent late diagnosis of the second lesions, with resultant advanced staging, and therefore poor prognosis; 3. inability to institute the appropriate therapy for these lesions due to the effects of previous radical therapy utilized for the first tumor. The clinical implications of this problem are discussed.

Entities:  

Mesh:

Year:  1983        PMID: 6823179     DOI: 10.1288/00005537-198301000-00014

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  15 in total

Review 1.  Clinico-prognostic value of D-type cyclins and p27 in laryngeal cancer patients: a review.

Authors:  L Pignataro; G Sambataro; D Pagani; G Pruneri
Journal:  Acta Otorhinolaryngol Ital       Date:  2005-04       Impact factor: 2.124

2.  Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirus-associated oropharyngeal cancer.

Authors:  Luc G T Morris; Andrew G Sikora; Snehal G Patel; Richard B Hayes; Ian Ganly
Journal:  J Clin Oncol       Date:  2010-12-28       Impact factor: 44.544

3.  Serum p53 antibodies as a prognostic indicator in oral squamous cell carcinoma.

Authors:  Yutaka Yamazaki; Itsuo Chiba; Makoto Ishikawa; Chiharu Satoh; Ken-Ichi Notani; Yoichi Ohiro; Yasunori Totsuka; Shigeaki Mizuno; Yoshimasa Kitagawa
Journal:  Odontology       Date:  2008-07-27       Impact factor: 2.634

4.  Second malignant tumours in head and neck cancer.

Authors:  G R Ogden
Journal:  BMJ       Date:  1991-01-26

Review 5.  Solid tumor second primary neoplasms: who is at risk, what can we do?

Authors:  Kevin C Oeffinger; Shrujal S Baxi; Danielle Novetsky Friedman; Chaya S Moskowitz
Journal:  Semin Oncol       Date:  2013-12       Impact factor: 4.929

Review 6.  Oesophageal cancer--an overview.

Authors:  Michael Schweigert; Attila Dubecz; Hubert J Stein
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-01-08       Impact factor: 46.802

7.  Preoperative evaluation of patients with primary head and neck cancer using dual-head 18fluorodeoxyglucose positron emission tomography.

Authors:  M P Stokkel; F W ten Broek; G J Hordijk; R Koole; P P van Rijk
Journal:  Ann Surg       Date:  2000-02       Impact factor: 12.969

8.  Proto-oncogene allelic variations in human squamous cell carcinomas of the larynx.

Authors:  R Dolcetti; S Pelucchi; R Maestro; S Rizzo; A Pastore; M Boiocchi
Journal:  Eur Arch Otorhinolaryngol       Date:  1991       Impact factor: 2.503

Review 9.  Chemoprevention of lung cancer.

Authors:  Edward S Kim; Fadlo R Khuri
Journal:  Curr Oncol Rep       Date:  2002-07       Impact factor: 5.075

10.  Relationships of vitamins A and E and beta-carotene serum levels to head and neck cancer patients with and without second primary tumors.

Authors:  N de Vries; G B Snow
Journal:  Eur Arch Otorhinolaryngol       Date:  1990       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.